HCC study

Establishing A Hematology Consortium in India (HCC study)

Study design / Type : 

Haematological cancers are highly curable cancers if diagnosed early and treated appropriately.

The delivery of treatment in our country has several limitations and challenges that are unique. There is an urgent felt need for haematological cancers in India to develop a large data base of patients treated in India, develop data-based understanding of existing challenges and move forward with evidence-based locally relevant treatment protocols and guidelines. To do this, it is essential to develop a platform for large multi-centre collaboration in collating data and ability to do prospective clinical trials to answer regionally relevant questions. This platform will also be used to train health care professionals, encourage basic science and translational research in this field and be a platform to provide knowledge resource for physicians, patients and for patient advocacy. The lead investigators plan to establish the Haematology Cancer Consortium (HCC) to fulfil the above-mentioned objectives. HCC anticipates to establish itself as  a  non-conflicted voice for improving evidence based and cost effective care for haematological malignancies in India. HCC also envisions its role in partnering basic scientists, research organizations, government and non-governmental agencies to improve care and access to quality care for patients with haematological malignancies in India.

The 4 main activities include:

1.Establish a multicenter registry of common hematological cancers.

2.Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation study
Sample size 300

3.Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic phase chronic myeloid leukemia - A multi-center phase II single arm study
Sample size 90

4.COVID-19 Hematological Cancers Registry Of India (CHCRI)
Sample size 750